Ocrevus (ocrelizumab): best clinics abroad

Ocrevus contains ocrelizumab, a monoclonal antibody that targets CD20-positive B cells involved in multiple sclerosis. It is a disease modifying treatment intended to reduce disease activity and slow disability progression in eligible patients. It does not cure MS or reliably reverse established damage, and it is different from medicines used to manage an acute relapse or individual symptoms.

Eligibility depends on the form and activity of MS, previous treatment, health risks and the rules in the treatment country. European indications include active relapsing MS and selected early primary progressive disease with inflammatory imaging features. Intravenous and subcutaneous formulations are available in some countries, with different administration instructions. A specialist team reviews infections, hepatitis B status, immunity, vaccinations and other safety factors before treatment. Repeated administration requires ongoing monitoring, because infusion or injection reactions, infection and other important adverse effects can occur. Patients may consider care abroad for specialist reassessment or access to an eligible formulation; agree repeated administration, safety checks and uninterrupted follow-up with the centre and clinicians at home.

Who may be eligible

A neurologist reviews relapses, MRI activity, disability, disease duration and earlier treatments. Ocrelizumab may be appropriate for active relapsing disease or particular primary progressive cases. Local authorisation and access criteria differ, so a diagnosis of progressive MS alone does not establish eligibility. Compare options within the wider plan for medication treatment for multiple sclerosis.

Checks before treatment

Assessment includes hepatitis B screening, review of active or recurrent infections and blood tests appropriate to the formulation and local protocol, including immunoglobulins and liver tests. Previous hepatitis B may require specialist input because reactivation is possible. Active infection can delay administration. Tell the team about other immune treatments, cancer history and all prescribed medicines.

Vaccination plans should be reviewed before treatment. Responses to some vaccines can be reduced, and live vaccines require special precautions while immunity is affected. Pregnancy, contraception and breastfeeding need a personalised plan; do not change treatment timing without the MS team. Infant vaccine advice may also be needed after exposure during pregnancy.

Administration and ongoing review

Depending on the authorised product, treatment is given as a vein infusion or an injection under the skin by trained staff. These formulations have different preparation and administration instructions and are not interchangeable by using the same volume. Preventive medicines and observation help manage reactions. The prescribed schedule and any change of formulation are set by the treating team.

Follow-up assesses relapses, MRI findings, function and tolerability alongside infection risk and laboratory results. Rehabilitation and symptom care remain important even when inflammatory disease activity falls. A missed dose, new infection or planned operation should be discussed with the team rather than managed by independent rescheduling.

Frequently asked questions

Will it immediately treat a relapse?

No. Ocrelizumab modifies future disease activity. New symptoms require assessment for relapse, infection or another cause and may need separate treatment.

What reactions should be reported?

Tell staff promptly about itching, rash, throat symptoms, dizziness or breathing difficulty during or after administration. Severe reactions require urgent care.

Which symptoms need medical advice between doses?

Report fever or persistent infection, new unusual neurological changes, persistent severe diarrhoea, jaundice or dark urine. Rare serious complications can include brain infection, bowel inflammation and liver injury.

Can monitoring stop if I feel well?

No. Safety checks and regular MS assessment remain necessary. Follow routine cancer screening and report changes to the clinical team.